Pixium Vision announces receipt of € 1.8 million from the French Government as Research Tax Credit

Pixium Vision announces receipt of € 1.8 million from the French Government as Research Tax Credit

• €1.8 million research tax credit received on June 7, 2023, to extend runway to the end of September 2023
• Lloyd Diamond participates at the Octane Ophthalmology Tech Forum
• Edison published an updated analyst report  
  
  

Paris, France, June 8, 2023 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that it has received a € 1.8 million Research Tax Credit.

This cash injection will help extend the company’s cash runway until the end of September 2023, providing more flexibility to pursue its longer-term funding needs to support its strategic ambitions.

CEO Lloyd Diamond commented: “We remain convinced that the Prima System could offer real hope to Dry AMD (Geographic Atrophy) and retinal disease patients, and this cash injection will provide Pixium with enhanced resources strengthening our position in partnering discussions with investors. It is becoming increasingly evident that in the future, patients suffering from other profound central vision impairment should also be able to benefit from the Prima Bionic Vision System.” “The recent FDA breakthrough device designation granted this past March 2023 gives us further confidence in the potential of photovoltaic neurostimulation to restore vision in patients suffering from retinal degenerative diseases” he added.

Pixium Vision continues to focus on their pivotal European study assessing the safety and clinical benefits of the wireless PRIMA System in patients with geographic atrophy due to age-related macular degeneration (GA-AMD). Having completed the required 38 implantations of the “PRIMAvera study” in late 2022, the top-line data are expected around year-end 2023 and EU market approval in 2024.

Furthermore, Pixium Vision announces participation at the Octane Ophthalmology Tech Forum.

• EXPERIENCE: Partnership Pursuit: Physician & Entrepreneur Reception (by invite only)
  • Thursday June 8th, 4:30 – 5:30 pm PST - Mariner Room

•  LUNCH & EXPERIENCE: Capital and Growth Main Stage Presentation
  • Friday, June 9^th 1:15 - 2:30 pm- Grand Ballroom
  • Andrew Douglas, Partner, Knobbe Martens (Moderator)